Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.24
STE's Cash to Debt is ranked higher than
53% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. STE: 0.24 )
STE' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.24

Equity to Asset 0.52
STE's Equity to Asset is ranked higher than
62% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. STE: 0.52 )
STE' s 10-Year Equity to Asset Range
Min: 0.43   Max: 0.86
Current: 0.52

0.43
0.86
Interest Coverage 11.02
STE's Interest Coverage is ranked higher than
62% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. STE: 11.02 )
STE' s 10-Year Interest Coverage Range
Min: 1.31   Max: 76.18
Current: 11.02

1.31
76.18
F-Score: 3
Z-Score: 4.03
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.75
STE's Operating margin (%) is ranked higher than
81% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. STE: 12.75 )
STE' s 10-Year Operating margin (%) Range
Min: 3.02   Max: 17.1
Current: 12.75

3.02
17.1
Net-margin (%) 7.98
STE's Net-margin (%) is ranked higher than
76% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. STE: 7.98 )
STE' s 10-Year Net-margin (%) Range
Min: -5.2   Max: 10.65
Current: 7.98

-5.2
10.65
ROE (%) 12.46
STE's ROE (%) is ranked higher than
84% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. STE: 12.46 )
STE' s 10-Year ROE (%) Range
Min: -10.38   Max: 19.48
Current: 12.46

-10.38
19.48
ROA (%) 6.86
STE's ROA (%) is ranked higher than
81% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.19 vs. STE: 6.86 )
STE' s 10-Year ROA (%) Range
Min: -5.67   Max: 10.37
Current: 6.86

-5.67
10.37
ROC (Joel Greenblatt) (%) 28.65
STE's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.08 vs. STE: 28.65 )
STE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.07   Max: 39.85
Current: 28.65

5.07
39.85
Revenue Growth (%) 10.60
STE's Revenue Growth (%) is ranked higher than
84% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. STE: 10.60 )
STE' s 10-Year Revenue Growth (%) Range
Min: -6.3   Max: 10.6
Current: 10.6

-6.3
10.6
EBITDA Growth (%) 26.60
STE's EBITDA Growth (%) is ranked higher than
92% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. STE: 26.60 )
STE' s 10-Year EBITDA Growth (%) Range
Min: -18.3   Max: 67.8
Current: 26.6

-18.3
67.8
EPS Growth (%) 36.70
STE's EPS Growth (%) is ranked higher than
93% of the 239 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. STE: 36.70 )
STE' s 10-Year EPS Growth (%) Range
Min: -72.2   Max: 293.6
Current: 36.7

-72.2
293.6
» STE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

STE Guru Trades in Q3 2013

Jim Simons 348,500 sh (+148.75%)
Vanguard Health Care Fund 803,083 sh (unchged)
Mario Gabelli 120,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 1,695,861 sh (-0.49%)
Chuck Royce 1,176,808 sh (-4.87%)
Paul Tudor Jones 11,000 sh (-50.67%)
Steven Cohen 7,196 sh (-73.34%)
» More
Q4 2013

STE Guru Trades in Q4 2013

Vanguard Health Care Fund 803,083 sh (unchged)
Chuck Royce 1,176,808 sh (unchged)
Mario Gabelli 120,000 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 1,654,036 sh (-2.47%)
Paul Tudor Jones 9,601 sh (-12.72%)
Jim Simons 28,200 sh (-91.91%)
» More
Q1 2014

STE Guru Trades in Q1 2014

Joel Greenblatt 16,049 sh (New)
Mario Gabelli 120,000 sh (unchged)
Chuck Royce 1,176,808 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund Sold Out
Ken Fisher 1,611,856 sh (-2.55%)
Paul Tudor Jones 6,900 sh (-28.13%)
» More
Q2 2014

STE Guru Trades in Q2 2014

Jim Simons 31,800 sh (New)
Paul Tudor Jones 15,800 sh (+128.99%)
Joel Greenblatt 17,236 sh (+7.4%)
Chuck Royce 1,159,308 sh (-1.49%)
Ken Fisher 1,586,711 sh (-1.56%)
Mario Gabelli 113,000 sh (-5.83%)
» More
» Details

Insider Trades

Latest Guru Trades with STE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-03-31 Sold Out 0.12%$43.58 - $49.76 $ 5517%0
Joel Greenblatt 2014-03-31 New Buy0.01%$43.58 - $49.76 $ 5517%16049
Joel Greenblatt 2013-09-30 Sold Out 0.02%$40.76 - $45.85 $ 5527%0
Joel Greenblatt 2013-06-30 Reduce -82.59%0.1%$39.02 - $46.34 $ 5528%9904
Joel Greenblatt 2013-03-31 Reduce -30.67%0.05%$34.73 - $41.61 $ 5544%56876
Joel Greenblatt 2012-12-31 Reduce -27.22%0.07%$32.37 - $36.63 $ 5559%82042
Joel Greenblatt 2012-12-31 Reduce -27.22%0.07%$32.37 - $36.63 $ 5559%82042
Mario Gabelli 2012-12-31 Add 20.48%$32.37 - $36.63 $ 5559%100000
Joel Greenblatt 2012-09-30 Add 85.37%0.12%$29.95 - $36.12 $ 5566%112726
Mario Gabelli 2012-09-30 Add 50.91%0.01%$29.95 - $36.12 $ 5566%83000
Joel Greenblatt 2012-06-30 Add 105.8%0.07%$28.97 - $31.59 $ 5581%60811
David Dreman 2012-03-31 Sold Out 0.66%$28.1 - $32.27 $ 5590%0
Joel Greenblatt 2012-03-31 New Buy0.08%$28.1 - $32.27 $ 5590%29548
Mario Gabelli 2012-03-31 Add 96.43%0.01%$28.1 - $32.27 $ 5590%55000
Mario Gabelli 2011-12-31 Add 27.27%$27.38 - $32.42 $ 5588%28000
Mario Gabelli 2011-09-30 New Buy0.01%$27.95 - $36.72 $ 5571%22000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.90
STE's P/E(ttm) is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.90 vs. STE: 24.90 )
STE' s 10-Year P/E(ttm) Range
Min: 11.06   Max: 54.91
Current: 24.9

11.06
54.91
P/B 2.90
STE's P/B is ranked higher than
64% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.02 vs. STE: 2.90 )
STE' s 10-Year P/B Range
Min: 1.68   Max: 3.11
Current: 2.9

1.68
3.11
P/S 1.97
STE's P/S is ranked higher than
70% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. STE: 1.97 )
STE' s 10-Year P/S Range
Min: 0.94   Max: 2
Current: 1.97

0.94
2
PFCF 20.10
STE's PFCF is ranked higher than
87% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 65.30 vs. STE: 20.10 )
STE' s 10-Year PFCF Range
Min: 8.72   Max: 114.75
Current: 20.1

8.72
114.75
EV-to-EBIT 16.55
STE's EV-to-EBIT is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. STE: 16.55 )
STE' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 29
Current: 16.55

7.2
29
PEG 7.00
STE's PEG is ranked higher than
85% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. STE: 7.00 )
STE' s 10-Year PEG Range
Min: 0.53   Max: 22.76
Current: 7

0.53
22.76
Shiller P/E 25.70
STE's Shiller P/E is ranked higher than
86% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. STE: 25.70 )
STE' s 10-Year Shiller P/E Range
Min: 14.83   Max: 35.66
Current: 25.7

14.83
35.66
Current Ratio 2.93
STE's Current Ratio is ranked higher than
73% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. STE: 2.93 )
STE' s 10-Year Current Ratio Range
Min: 1.49   Max: 5.39
Current: 2.93

1.49
5.39
Quick Ratio 2.15
STE's Quick Ratio is ranked higher than
75% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.09 vs. STE: 2.15 )
STE' s 10-Year Quick Ratio Range
Min: 1.18   Max: 4.85
Current: 2.15

1.18
4.85

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.53
STE's Dividend Yield is ranked higher than
61% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. STE: 1.53 )
STE' s 10-Year Dividend Yield Range
Min: 0.15   Max: 2.34
Current: 1.53

0.15
2.34
Dividend Payout 0.41
STE's Dividend Payout is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. STE: 0.41 )
STE' s 10-Year Dividend Payout Range
Min: 0.1   Max: 0.51
Current: 0.41

0.1
0.51
Dividend growth (3y) 13.60
STE's Dividend growth (3y) is ranked higher than
86% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. STE: 13.60 )
STE' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 34.7
Current: 13.6

0
34.7
Yield on cost (5-Year) 3.22
STE's Yield on cost (5-Year) is ranked higher than
85% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. STE: 3.22 )
STE' s 10-Year Yield on cost (5-Year) Range
Min: 0.32   Max: 5.02
Current: 3.22

0.32
5.02
Share Buyback Rate 0.20
STE's Share Buyback Rate is ranked higher than
85% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.20 vs. STE: 0.20 )
STE' s 10-Year Share Buyback Rate Range
Min: 4.8   Max: -22
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.80
STE's Price/Tangible Book is ranked lower than
58% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.50 vs. STE: 18.80 )
STE' s 10-Year Price/Tangible Book Range
Min: 2.69   Max: 18.25
Current: 18.8

2.69
18.25
Price/DCF (Projected) 1.80
STE's Price/DCF (Projected) is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. STE: 1.80 )
STE' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 14.78
Current: 1.8

0.82
14.78
Price/Median PS Value 1.30
STE's Price/Median PS Value is ranked higher than
58% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. STE: 1.30 )
STE' s 10-Year Price/Median PS Value Range
Min: 0.54   Max: 4.59
Current: 1.3

0.54
4.59
Price/Peter Lynch Fair Value 2.30
STE's Price/Peter Lynch Fair Value is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. STE: 2.30 )
STE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.45   Max: 41.83
Current: 2.3

0.45
41.83
Price/Graham Number 4.70
STE's Price/Graham Number is ranked higher than
65% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.60 vs. STE: 4.70 )
STE' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 11.56
Current: 4.7

1.17
11.56
Earnings Yield (Greenblatt) 5.80
STE's Earnings Yield (Greenblatt) is ranked higher than
72% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. STE: 5.80 )
STE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 13.9
Current: 5.8

3.4
13.9
Forward Rate of Return (Yacktman) 14.44
STE's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.15 vs. STE: 14.44 )
STE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.9   Max: 38.6
Current: 14.44

3.9
38.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:STQ.Germany
Steris Corporation was founded as Innovative Medical Technologies in Ohio in 1985, and renamed STERIS Corporation in 1987. The Company is a provider of infection prevention and other procedural products and services, focused mainly on healthcare, pharmaceutical and research. It offers a mix of capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room ('OR') integration; consumable products, such as detergents and skin care products, gastrointestinal ('GI') endoscopy accessories, and other products; services, including equipment installation and maintenance; and microbial reduction of medical devices, instrument and scope repair solutions, and laboratory testing services. The Company operates in three business segments: Healthcare, Life Sciences, and STERIS Isomedix Services. 'Corporate and other,' which is presented separately, contains the Defense and Industrial business unit plus costs that, are associated with being a publicly traded Company and certain other corporate costs. The Company's Healthcare segment manufactures and sells capital equipment, accessory, consumable, and service solutions to healthcare providers, including acute care hospitals, and surgery and gastrointestinal centers. Brand names for these products include, SYSTEM 1E, Amsco, Hamo, Reliance, Cmax, Harmony, Kindest Kare, Alcare, Verify, Cal Stat, and Roth Net. Its Life Sciences segment manufactures and sells engineered capital equipment, formulated cleaning chemistries, and service solutions to pharmaceutical companies, and private and public research facilities around the globe. Brand names for these products include Amsco, Reliance, Finn-Aqua, VHP, and the CIP Products. Its Isomedix segment operates through a network of facilities located in North America. It sells an array of materials processing services using gamma irradiation, and ethylene oxide ('EO') technologies. It provides microbial reduction services based on Customer specifications to companies that supply products to the healthcare, industrial, and consumer products industries. Its competitors include Belimed, Ecolab, Fedegari, Getinge, MECO, Stilmas, Techniplast, Sterigenics International, Inc. The Company is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and in other countries.
» More Articles for STE

Headlines

Articles On GuruFocus.com
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
Supply Your Portfolio with Healthy Growth from Medical Suppliers May 25 2012 
STERIS Corp. Reports Operating Results (10-Q) Feb 09 2011 
STERIS Corp. Reports Operating Results (10-Q) Nov 09 2010 
STERIS Corp. (STE) President & CEO Walter M Jr Rosebrough sells 11,600 Shares Oct 01 2010 
STERIS Corp. (STE) SVP & CFO Michael J Tokich sells 9,000 Shares Apr 09 2010 
STERIS Corp. Reports Operating Results (10-Q) Feb 09 2010 
Robert Olstein on Hedge Fund regulations. Recent Olstein buys. Jan 15 2010 
STERIS Corp. Reports Operating Results (10-Q) Nov 03 2009 
STERIS Corp. (STE) President & CEO Walter M Jr Rosebrough sells 5,000 Shares Oct 02 2009 

More From Other Websites
STERIS CORP Financials Aug 15 2014
Steris (STE) Misses on Q1 Earnings and Revenues, Both Up Y/Y Aug 08 2014
STERIS CORP Files SEC form 10-Q, Quarterly Report Aug 08 2014
STERIS Corporation Announces Fiscal 2015 First Quarter Results Aug 05 2014
STERIS Corp Earnings Call scheduled for 10:00 am ET today Aug 05 2014
STERIS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters... Aug 05 2014
Q1 2015 STERIS Corporation Earnings Release - Before Market Open Aug 05 2014
STERIS Corporation Announces Fiscal 2015 First Quarter Results Aug 05 2014
Bob McNamara, the Executive Vice President and CFO of LDR Holding Corporation (LDRH), Interviews... Aug 01 2014
STERIS Corporation to Announce Fiscal 2015 First Quarter Financial Results on August 5, 2014 Jul 22 2014
STERIS Corporation to Announce Fiscal 2015 First Quarter Financial Results on August 5, 2014 Jul 22 2014
Steris unit received FDA warning letter in May Jun 03 2014
STERIS CORP Files SEC form 10-K, Annual Report May 29 2014
STERIS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... May 09 2014
STERIS' (STE) CEO Walter Rosebrough on Q4 2014 Results - Earnings Call Transcript May 08 2014
STERIS Corporation Earnings Call scheduled for 10:00 am ET today May 08 2014
STERIS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2014
Steris sees FY15 adjusted EPS $2.78-$2.91, consensus $2.76 May 08 2014
Steris reports Q4 adjusted EPS 91c, consensus 86c May 08 2014
STERIS Corporation Announces Fiscal 2014 Fourth Quarter and Full Year Results May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide